Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,901–5,000 of 15,747
HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions
Zhou, K., Yuzhakov, O., Behloul, N., Wang, D., Bhagat, L., Chu, D., Zhang, X., Cheng, X., Fan, L., Huang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213285 · Cited by 26
“The recent success of mRNA-based COVID vaccines Spikevax® and Comirnaty® in controlling the pandemic demonstrates the safety and potency of this unconventional approach, as well as its adaptability for addressing future public health emergencies (11, 12).”
BackgroundMethodInfluentialAppendicitis as a possible safety signal for the COVID-19 vaccines
Mitchell, J., & Yue, Q. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100122 · Cited by 19
“The COVID-19 vaccines produce robust Th1 immune responses [3,5,17,22] and there is a hypothesised link between”
Kałucka, S., Kusideł, E., Głowacka, A., Oczoś, P., & Grzegorczyk-Karolak, I. (2022) · Vaccines · doi:10.3390/vaccines10030401 · Cited by 37
“The Polish government first purchased the two-dose vaccines BNT162b2 mRNA COVID-19 by BioNTech/Pfizer [13], ChAdOX1nCoV-19 by AstraZeneca [14], and mRNA-1273 SARS-CoV2 vaccine by Moderna [15], followed by the single-dose Ad26.”
MethodBanerjee, A., Lew, J. M., Kroeker, A., Baid, K., Aftanas, P., Nirmalarajah, K., Maguire, F., Kozak, R. A., McDonald, R. R., Lang, A. L. S., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.002 · Cited by 19
“The current generation of COVID-19 mRNA vaccines are designed using the spike gene sequence of ancestral SARS-CoV-2.(9,10) The Omicron variant has accumulated 29 amino acid substitutions, three amino acid deletions, and a three-residue insertion within the spike protein compared to the ancestral SARS-CoV-2 Wuhan isola…”
Malhotra, A. (2022) · Journal of Metabolic Health · doi:10.4102/jir.v5i1.71 · Cited by 20
Rifai, M. A., Khalid, U., Misra, A., Liu, J., Nasir, K., Cainzos‐Achirica, M., Mahtta, D., Ballantyne, C. M., Petersen, L. A., & Virani, S. S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100150 · Cited by 19
Aseptic meningoencephalitis after COVID-19 vaccination: A case report
Ahmad, S. A., Salih, B. K., Hussein, K. F. H., Mikael, T. M., Kakamad, F. H., & Salih, A. M. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.103028 · Cited by 18
Wang, Z., Chen, J., Zhu, C., Liu, L., Qi, T., Shen, Y., Zhang, Y., Xu, L., Li, T., Qian, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.568789 · Cited by 19
Martin, D. E., Cadar, A. N., & Bartley, J. M. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1272336 · Cited by 22
Thurm, C., Reinhold, A., Borucki, K., Kahlfuß, S., Feist, E., Schreiber, J., Reinhold, D., & Schraven, B. L. (2022) · Vaccines · doi:10.3390/vaccines10020333 · Cited by 19
Quinn, K. L., Huang, A., Bell, C. M., Detsky, A. S., Lapointe‐Shaw, L., Rosella, L. C., Urbach, D. R., Razak, F. A., & Verma, A. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.47341 · Cited by 20
Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern
Chaouat, A. E., Brizić, I., Brlić, P. K., Atari, N., Kliker, L., Alfi, O., Mandelboim, M., Wolf, D. G., Tafish, L., Kol, I., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104935 · Cited by 17
Efrati, S., Catalogna, M., Hamad, R. A., Hadanny, A., Bar‐Chaim, A., Benveniste‐Levkovitz, P., & Levtzion‐Korach, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-96129-6 · Cited by 20
Li, Y. E., Wang, S., Reiter, R. J., & Ren, J. T. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.026 · Cited by 26
Heo, J. Y., Seo, Y. B., Kim, E. J., Lee, J., Kim, Y. R., Yoon, J. G., Noh, J. Y., Cheong, H. J., Kim, W. J., Yoon, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975363 · Cited by 23
“Systemic reactogenicity following BNT162b2 vaccination is more common and severe after the second dose (3).”
BackgroundInfluentialSputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art
Gushchin, V. А., Tsyganova, E. V., Ogarkova, D. A., Adgamov, R. R., Shcheblyakov, D. V., Glukhoedova, N. V., Zhilenkova, A. S., Kolotii, A. G., Zaitsev, R. D., Logunov, D. Y., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101360 · Cited by 21
Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients
Zhou, Z., Li, D., Zhao, Z., Shi, S., Wu, J., Li, J., Zhang, J., Gui, K., Zhang, Y. L., Ouyang, Q., et al. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011383 · Cited by 19
Saharia, K., Anjan, S., Streit, J. A., Beekmann, S. E., Polgreen, P. M., Kuehnert, M. J., Segev, D. L., Baddley, J. W., Miller, R. A., & the EIN COVID‐19 Study Team (2022) · Transplant Infectious Disease · doi:10.1111/tid.13774 · Cited by 20
Lau, H.-C., Passalacqua, I., Jung, J., Kwon, Y., Zocco, D., Park, S., & Oh, S. W. (2024) · Scientific Reports · doi:10.1038/s41598-023-50279-x · Cited by 21
“For instance, in the results of clinical trials for both BioNTech/Pfizer and Moderna vaccines, a significant percentage of subjects presented local and systemic adverse events 3,4 .”
ResultPharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines
Hofman, K., Shenoy, G. N., Chak, V., & Balu‐Iyer, S. V. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1904977 · Cited by 20
“cases, only 8 cases were in the BNT162b2 treatment group thus conferring protective efficacy of 95% (Polack et al. 2020).”
BackgroundYeshurun, M., Pasvolsky, O., Shargian, L., Yahav, D., Ben‐Zvi, H., Rubinstein, M., Sela-Navon, M., Wolach, O., Raanani, P., & Rozovski, U. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.007 · Cited by 19
“Pu evaluating severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines [3].”
Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates
Collett, S., Earnest, L., Montoya, J. C., Edeling, M. A., Yap, A. H. Y., Wong, C. Y., Christiansen, D., Roberts, J., Mumford, J., Lecouturier, V., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1065609 · Cited by 21
Shrivastava, S., Carmen, J. M., Lu, Z., Basu, S., Sankhala, R. S., Chen, W., Nguyen, P., Chang, W. C., King, J., Corbitt, C., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00638-6 · Cited by 20
Eberle, R. J., Gering, I., Tusche, M., Ostermann, P. N., Müller, L., Adams, O., Schaal, H., Olivier, D. S., do Amaral, M. S., Arni, R. K., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15050540 · Cited by 18
“BioNTech-Pfizer, Moderna, Johnson & Johnson, and AstraZeneca vaccines) [3-6], and so far, more than 7 billion vaccine doses have been administered [2].”
BackgroundMethodHajra, A., Gupta, M., Ghosh, B., Ashish, K., Patel, N., Manek, G., Rai, D. A., Sreenivasan, J., Goel, A., Lavie, C. J., et al. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00511-8 · Cited by 20
Mise‐Omata, S., Ikeda, M., Takeshita, M., Uwamino, Y., Wakui, M., Arai, T., Yoshifuji, A., Murano, K., Siomi, H., Nakagawara, K., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200525 · Cited by 22
Do we miss rare adverse events induced by COVID-19 vaccination?
Afshar, Z. M., Pirzaman, A. T., Liang, J. J., Sharma, A., Pirzadeh, M., Babazadeh, A., Hashemi, E., Deravi, N., Abdi, S., Allahgholipour, A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.933914 · Cited by 24
Post-COVID pandemic: The new normal and aftermath
Selvam, K. P., Kosalram, K. B., & Chinnaiyan, S. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_313_24 · Cited by 27
“[12] Global vaccination campaigns were initiated with unparalleled swiftness, offering optimism for managing the transmission of the virus and mitigating the intensity of illness.”
Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases
Iyer, S., Yadav, R. T., Agarwal, S., Tripathi, S., & Agarwal, R. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00123-21 · Cited by 23
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
Chaouat, A. E., Achdout, H., Kol, I., Berhani, O., Roi, G., Vitner, E. B., Melamed, S., Politi, B., Zahavy, E., Brizić, I., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010175 · Cited by 22
Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older
Choi, Y. Y., Kim, M.-K., Kwon, H. C., & Kim, G. H. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e318 · Cited by 20
Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2
Juang, Y.-P., Chou, Y.-T., Lin, R., Ma, H., Chao, T., Jan, J., Chang, S., & Liang, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114295 · Cited by 21
Cohen, D., Krauthammer, S. H., Wolf, I., & Even-Sapir, E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05579-7 · Cited by 19
Low, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2021) · doi:10.1101/2021.07.01.21259831 · Cited by 19
Wolszczak-Biedrzycka, B., Bieńkowska, A., & Dorf, J. (2021) · Vaccines · doi:10.3390/vaccines9121508 · Cited by 20
“The highest, 95% effectiveness was attained 7 days after the second vaccine dose [12,13].”
BackgroundOu, L., Chen, S. J., Teng, I., Yang, L., Zhang, B., Zhou, T., Biju, A., Cheng, C., Kong, W., Morano, N. C., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011584 · Cited by 19
“It will be interesting to see if v3B_ Δ 12_D454C-V458C can induce high titer responses in humans, whether delivered as a protein subunit vaccine with adjuvant as we have done here or delivered as a lipid-encapsulated mRNA-encoded vaccine, as has been done for SARS-CoV-2 [53,54] and is being tested clinically with othe…”
BackgroundTesting for SARS-CoV-2: lessons learned and current use cases
Theel, E. S., Kirby, J. E., & Pollock, N. R. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-23 · Cited by 21
“They documented protection from SARS-CoV-2 infection within 10 days of vaccination, when virus-specific CD8+ T cells were elevated, yet nAb were not yet routinely detectable; these findings have subsequently been confirmed by additional independent studies (252, 253).”
Result(2021) · doi:10.1101/2021.12.23.21268293 · Cited by 85
“In late 2020 and early 2021 this was widely achieved (in the UK, France and 43 elsewhere) through vaccination with BNT162b2 (Pfizer–BioNTech) – a lipid nanoparticle44 formulated, nucleoside-modified RNA vaccine encoding prefusion stabilized SARS-CoV-2 45 spike; or ChAdOx1 nCoV-19 (AZD1222, Oxford–AstraZeneca), an aden…”
BackgroundZarabanda, D., Vukkadala, N., Phillips, K. M., Qian, Z. J., Mfuh, K. O., Hatter, M. J., Lee, I. T., Rao, V. K., Hwang, P. H., Domb, G., et al. (2021) · The Laryngoscope · doi:10.1002/lary.29935 · Cited by 20
Blom, J. M. C., Rivi, V., Tascedda, F., & Pani, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570899 · Cited by 31
Discovery and development of COVID ‐19 vaccine from laboratory to clinic
Saravanan, V., Chagaleti, B. K., Narayanan, P. L., Anandan, V. B., Manoharan, H., Anjana, G. V., Peraman, R., Namasivayam, S. K. R., Kavisri, M., Arockiaraj, J., et al. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14383 · Cited by 22
“This mRNA instructs cells in the body to produce a protein that is found on the surface of the SARS-CoV-2 virus, which causes COVID-19 (Polack et al., 2020).”
BackgroundBorghi, M. O., Bombaci, M., Bodio, C., Lonati, P. A., Gobbini, A., Lorenzo, M., Torresani, E., Dubini, A., Bulgarelli, I., Solari, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930074 · Cited by 19
“literature (18) and are shown in Supplementary Table 2; no severe side effects were reported.”
BackgroundTrivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response
Mazunina, E. P., Gushchin, V. А., Kleymenov, D. A., Siniavin, A. E., Ei, B., Шмаров, М. М., Мукашева, Е. А., Bykonia, E. N., Kozlova, S. R., Evgrafova, E. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381508 · Cited by 26
“…employed in the development of new in fl uenza vaccines, including virus-like particles, DNA/mRNA vaccines, baculovirus expression system, viral vectors, et al. Of particular interest are mRNA-based vaccines, which have demonstrated their ef fi cacy and safety during the COVID-19 pandemic (14, 15).”
Ren, Z.-X., Nishimura, M., Tjan, L. H., Furukawa, K., Kurahashi, Y., Sutandhio, S., Aoki, K., Hasegawa, N., Arii, J., Uto, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266270 · Cited by 19
“The BNT162b2 mRNA vaccine (Comirnaty1, BioNTech-Pfizer, Mainz, Germany/New York, USA) [9] was approved first in Japan and administered to healthcare workers starting in February 2021, then to individuals aged �65 old beginning in April 2021, expanding to other populations from May 2021.”
BackgroundLokras, A. G., Chakravarty, A., Rades, T., Christensen, D., Franzyk, H., Thakur, A., & Foged, C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122171 · Cited by 23
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
Andersson, N. W., Thiesson, E. M., Hansen, J. V., & Hviid, A. P. (2023) · BMJ · doi:10.1136/bmj-2023-075015 · Cited by 22
mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA
Chaves, L. C. S., Orr‐Burks, N., Vanover, D. A., Mosur, V. V., Hosking, S. R., K., P. K. E., Jeong, H., Jung, Y., Assumpção, J. A. F., Peck, H. E., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012345 · Cited by 21
Al-Jipouri, A., Eritja, À., & Božić, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010485 · Cited by 24
Bates, S. M., Munson, M. J., Trovisco, V., Pereira, S. G. T., Miller, S. R., Sabirsh, A., Betts, C. J., Blenke, E. O., & Gay, N. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114047 · Cited by 31
The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 28
“The BioNTech/Pfizer vaccine exhibited a 95% efficacy in phase 3 of clinical trials [26], and more recently, another study was released showing that efficacy was maintained over a period of 6 months, irrespective of previous SARS-CoV-2 infections [27].”
MethodLiew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N. A., Siggins, M. K., Swieboda, D. P., Sidhu, J. K., Efstathiou, C., et al. (2022) · medRxiv · doi:10.1101/2022.09.09.22279759 · Cited by 19
Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines
Neto, A. R. D. S., de Carvalho, A. R. B., da Silva, M. D. F., Neta, M. M. R., Sena, I. V. D. O., Almeida, R. N., Filha, F. S. S. C., Silva, L. L. L. E., da Costa, G. R., Lira, I. M. D. S., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064796 · Cited by 21
Perceptions of COVID ‐19 vaccines among healthcare assistants: A national survey
Niznik, J. D., Harrison, J., White, E. M., Syme, M. L., Hanson, L. C., Kelley, C. J., Porter, L., & Berry, S. D. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17437 · Cited by 22
“Enrollment data suggest that although COVID-19 vaccine trials 28,29 have achieved greater representation than what has been achieved in most clinical trials, people of color are still underrepresented, despite the higher burden of severe illness in these populations.”
BackgroundHuỳnh, G., Nguyen, H. T. N., Viên, N. T., & An, P. L. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s301645 · Cited by 22
A Review of Different Vaccines and Strategies to Combat COVID-19
Sabitha, S., Shobana, N., Prakash, P., Padmanaban, S., Sathiyasree, M., Saigeetha, S., Chakravarthi, S., Uthaman, S., Park, I., & Samrot, A. V. (2022) · Vaccines · doi:10.3390/vaccines10050737 · Cited by 30
“It offers 95% protection against COVID-19 [51].”
Gutierrez-Alvarez, F. J., Honrubia, J. M., Sanz‐Bravo, A., González-Miranda, E., Fernández‐Delgado, R., Rejas, M. T., Zúñiga, S., Sola, I., & Enjuanes, L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111075118 · Cited by 19
Oosterhuis, I., Scholl, J. H. G., van Puijenbroek, E., Kant, A. C., & van Hunsel, F. P. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01253-5 · Cited by 20
Vernet, R., Charrier, E., Grogg, J., & Mach, N. (2021) · Vaccines · doi:10.3390/vaccines9070770 · Cited by 19
James, N., & Menzies, M. (2022) · The European Physical Journal Special Topics · doi:10.1140/epjs/s11734-022-00430-y · Cited by 19
Adams, L. J., VanBlargan, L. A., Liu, Z., Gilchuk, P., Zhao, H., Chen, R. E., Raju, S., Chong, Z., Whitener, B. M., Shrihari, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101305 · Cited by 18
Barchuk, A., Cherkashin, M., Bulina, A., Berezina, N., Rakova, T., Kuplevatskaya, D., Stanevich, O., Skougarevskiy, D., & Okhotin, A. (2021) · medRxiv · doi:10.1101/2021.08.18.21262065 · Cited by 15
Fraley, E., LeMaster, C., Khanal, S., Banerjee, D., Pastinen, T., Grundberg, E., Selvarangan, R., & Bradley, T. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab850 · Cited by 18
“SARS-CoV-2 mRNA vaccines have been shown to be effective at preventing severe coronavirus disease 2019 (Covid-19) [1, 2].”
BackgroundTerpos, E., Karalis, V., Ntanasis‐Stathopoulos, I., Apostolakou, F., Gumeni, S., Gavriatopoulou, M., Papadopoulos, D., Malandrakis, P., Papanagnou, E.-D., Korompoki, E., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000677 · Cited by 20
SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma
Itell, H. L., Weight, H., Fish, C. S., Logue, J. K., Franko, N., Wolf, C. R., McCulloch, D. J., Galloway, J., Matsen, F. A., IV, Chu, H. Y., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01298-21 · Cited by 21
Crombé, A., Bensid, L., Seux, M., Fadli, D., Arnaud, F., Benhamed, A., Banaste, N., & Gorincour, G. (2023) · Radiology · doi:10.1148/radiol.222730 · Cited by 19
“Minimal 49/284 (17) 116/717 (16) 98/753 (13) 90/748 (12)”
Nakhostin-Ansari, A., Zimet, G. D., Khonji, M. S., Aghajani, F., Teymourzadeh, A., Kazerooni, A. R., Pirayandeh, P., Aghajani, R., Safari, S., Khalaj, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10050670 · Cited by 24
“Design After phase III clinical trials confirmed the safety and efficacy of some COVID-19 vaccines, and the United States (US) Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech and Moderna COVID-19 vaccines, the current study was conducted as a cross-sectional study from 20 Decembe…”
BackgroundStrilchuk, A. W., Hur, W. S., Batty, P. A., Sang, Y., Abrahams, S. R., Yong, A. S. M., Leung, J., Silva, L. M., Schroeder, J. A., Nesbitt, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0027 · Cited by 22
Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load
Kennedy‐Shaffer, L., Kahn, R. J., & Lipsitch, M. (2021) · Epidemiology · doi:10.1097/ede.0000000000001415 · Cited by 22
“Individual randomized controlled trials (RCTs) conducted have shown high vaccine efficacy (VE) of several vaccine candidates in preventing symptomatic, laboratory-confirmed disease (2–5).”
BackgroundCOVID-19 vaccination programme: a central role for primary care
Harnden, A., Lim, W. S., & Earnshaw, A. (2021) · British Journal of General Practice · doi:10.3399/bjgp21x714929 · Cited by 19
Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs
Dzinamarira, T., Tungwarara, N., Chitungo, I. J. B., Chimene, M., Iradukunda, P. G., Mashora, M. C., Murewanhema, G., Rwibasira, G. N., & Musuka, G. (2022) · Vaccines · doi:10.3390/vaccines10020252 · Cited by 19
“This is because studies have demonstrated their effectiveness in reducing new infections, moderate and severe disease, hospitalization, and death among infected individuals [4,5].”
BackgroundDeng, J., Zhou, F., Hou, W., Heybati, K., Ali, S. H., Chang, O., Silver, Z. A., Dhivagaran, T., Ramaraju, H. B., Wong, C. Y., et al. (2022) · Future Virology · doi:10.2217/fvl-2021-0066 · Cited by 20
Andreica, I., Blazquez‐Navarro, A., Sokolar, J., Anft, M., Kiltz, U., Pfaender, S., Blanco, E. V., Westhoff, T. H., Babel, N., Stervbo, U., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002293 · Cited by 18
Luo, C., Chen, H., & Tung, T. (2022) · Vaccines · doi:10.3390/vaccines10081229 · Cited by 21
“Thus, as a response to the pandemic, safe and effective preventive vaccines were a potentially useful tool that could be used to reduce transmission rates and subsequent infections [5,6].”
BackgroundAntibody response to COVID-19 vaccination in patients with lymphoma
Narita, K., Nakaji, S., Tabata, R., Terao, T., Kuzume, A., Tsushima, T., Ikeda, D., Fukumoto, A., Miura, D., Takeuchi, M., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03305-z · Cited by 20
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
Efe, C., Taşçılar, K., Gerussi, A., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102906 · Cited by 19
“Importantly, patients who were on immunosuppressive therapy for conditions such as autoimmune hepatitis (AIH), inflammatory bowel diseases or after liver transplantation (LT) were not included in the phase 3 trials of mRNA-based vaccines [9,10].”
Sáez‐Llorens, X., Lanata, C. F., Aranguren, E., Celis, C. R., Cornejo, R., DeAntonio, R., Ecker, L., Garrido, D., Gil, A. I., Gonzales, M., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100189 · Cited by 22
Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N., Lima-Barbosa, R., Beaudoin-Bussières, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111013 · Cited by 18
“…of vaccine scarcity and given the significant protection already conferred by the first dose in non-high-risk populations (Baden et al., 2021; Polack et al., 2020; Skowronski and De Serres, 2021), some public health agencies implemented schedules with longer intervals to rapidly extend…”
BackgroundMa, M., Santosa, A., Fong, W., Chew, L., Low, A., Law, A., Poh, Y. J., Yeo, S., Leung, Y.-Y., Ng, V., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102959 · Cited by 17
Simulating Immunization Campaigns and Vaccine Protection Against COVID-19 Pandemic in Brazil
Amaral, F., Casaca, W. C. D. O., Oishi, C. M., et al. (2021) · IEEE Access · doi:10.1109/access.2021.3112036 · Cited by 19
Connolly, C. M., Koenig, D., Ravi, S. N., Azar, A., Kant, S., Dalal, M., Duchen, J., Seo, P., Antiochos, B., Paik, J. J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220972 · Cited by 20
Stopping the misinformation: BNT162b2 COVID-19 vaccine has no negative effect on women’s fertilityPreprint
Safrai, M., Rottenstreich, A., Herzberg, S., Imbar, T., Reubinoff, B. E., & Ben‐Meir, A. (2021) · medRxiv · doi:10.1101/2021.05.30.21258079 · Cited by 20
“Indeed, pregnant women and women trying to conceive were excluded from the pivotal clinical trials evaluating the mRNA-based vaccines (3,8,9).”
InfluentialBNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19
Ji, R.-R., Qu, Y., Zhu, H., Yang, Y., Vogel, A. B., Şahin, U., Qin, C., & Hui, A. (2021) · Vaccines · doi:10.3390/vaccines9040324 · Cited by 21
Self-citationPark, W. B., Hwang, Y. H., & Cheong, H. J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0023 · Cited by 19
Comprehensive Evaluation of the Toxicity and Biosafety of Plasma Polymerized Nanoparticles
Michael, P. L., Lam, Y. T., Hung, J., et al. (2021) · Nanomaterials · doi:10.3390/nano11051176 · Cited by 19
“The recent approval and widespread adoption of nanocarrierbased COVID-19 vaccines has demonstrated the immense potential of nanomedicine in impactful applications [9,10].”
BackgroundEpidemiological characteristics of the B.1.526 SARS-CoV-2 variant
Yang, W., Greene, S. K., Peterson, E. R., Li, W., Mathes, R. W., Graf, L. E., Lall, R., Hughes, S., Wang, J., & Fine, A. D. (2022) · Science Advances · doi:10.1126/sciadv.abm0300 · Cited by 20
Engineering CaP-Pickering emulsion for enhanced mRNA cancer vaccines via dual DC and NK activations
Wu, S., Zhou, Y., Asakawa, N., Wen, M., Sun, Y., Ming, Y., Song, T., Chen, W., Ma, G., & Xia, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.051 · Cited by 19
Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19
Li, C., Marton, I., Harari, D., Shemesh, M., Kalchenko, V., Pardo, M., Schreiber, G., & Rudich, Y. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00419 · Cited by 20
Myocarditis Following COVID-19 Vaccination: A Systematic Review of Case Reports.
Behers, B. J., Patrick, G., Jones, J. M., Carr, R. A., Behers, B. M., Melchor, J., Rahl, D. E., Guerriero, T. D., Zhang, H., Ozkardes, C., et al. (2022) · PubMed Central · Cited by 19
Khan, N. T., Zinnia, M. A., & Islam, A. B. M. M. K. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2024253 · Cited by 20
The top 100 most cited articles on COVID-19 vaccine: a bibliometric analysis
Wang, W., Wang, H., Yao, T., Li, Y., Yi, L., Gao, Y., Lian, J., Feng, Y., & Wang, S. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01046-9 · Cited by 23
The Experience of Greece as a Model to Contain COVID-19 Infection Spread
Delinasios, G. J., Fragkou, P. C., GKIRMPA, A. M., Tsangaris, G. T., Hoffman, R. M., & Anagnostopoulos, A. K. (2021) · In Vivo · doi:10.21873/invivo.12380 · Cited by 22
Godói, I. P. D., Sarmento, T. T. R., Reis, E. A., Gargano, L. P., Godman, B., Acúrcio, F. D. A., Álvares-Teodoro, J., Guerra, A. A., & Ruas, C. M. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1931128 · Cited by 21
“Up to January 2021, at least four vaccines had their randomized clinical trial (RCT) results published [19-22], even if preliminary, and had received the Emergency Use Authorization use in some countries including the United States of America, United Kingdom and Brazil [23-25].”
BackgroundAdvancements in RNA-based therapies from bench to bedside
Singh, A., Tekade, M., Nagaraja, S., Bharti, A., & Tekade, R. K. (2026) · npj Drug Discovery. · doi:10.1038/s44386-025-00037-y · Cited by 33
Sobczak, M., & Pawliczak, R. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00525-3 · Cited by 20
“Moreover, no deaths related with COVID-19 were reported during this clinical study [14].”
BackgroundCaironi, V., Pitoia, F., & Trimboli, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.900964 · Cited by 21
COVID-19 Vaccination Uptake and Hesitancy Among Current Tobacco Users
Krebs, N. M., D’Souza-Rushton, G. C., Bordner, C. R., Allen, S. I., Hobkirk, A. L., Foulds, J., & Yingst, J. M. (2021) · Tobacco Use Insights · doi:10.1177/1179173x211068027 · Cited by 22
Nguyễn, V. H., Boileau, C., Bogdanov, A., Sredl, M., Bonafede, M., Ducruet, T., Chavers, S., Rosen, A., Martin, D., Buck, P. O., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad288 · Cited by 23
“Data from clinical trials indicated high vaccine efficacy through to 6 months post-vaccination, particularly for mRNA vaccines [1-7].”
MethodBennett, C., Woo, W., Bloch, M., Cheung, K., Griffin, P., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., Neville, A. M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00077-x · Cited by 22
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.